See more : NAFCO Co., Ltd. (2790.T) Income Statement Analysis – Financial Results
Complete financial analysis of NeuroSense Therapeutics Ltd. (NRSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeuroSense Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Excelsior Biopharma Inc. (6496.TWO) Income Statement Analysis – Financial Results
- Vicinity Centres (VCX.AX) Income Statement Analysis – Financial Results
- Decollte Holdings Corporation (7372.T) Income Statement Analysis – Financial Results
- Pacific Century Regional Developments Limited (PCDVF) Income Statement Analysis – Financial Results
- Media Investment Optimization, S.A. (MIO.MC) Income Statement Analysis – Financial Results
NeuroSense Therapeutics Ltd. (NRSN)
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.00K | 89.00K | 3.00K | 3.00K | 0.00 |
| Gross Profit | -97.00K | -89.00K | -3.00K | -3.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.27M | 6.42M | 3.08M | 2.50M | 898.00K |
| General & Administrative | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.78M | 7.14M | 2.51M | 393.00K | 337.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Cost & Expenses | 10.29M | 13.55M | 5.59M | 2.89M | 1.24M |
| Interest Income | 178.00K | 91.00K | 0.00 | 61.00K | 18.00K |
| Interest Expense | 550.00K | 15.00K | 1.15M | 1.00K | 5.00K |
| Depreciation & Amortization | 97.00K | 89.00K | 3.00K | 3.00K | 1.24M |
| EBITDA | -10.63M | -13.38M | -2.88M | -2.83M | -1.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.05M | -13.55M | -5.59M | -2.89M | -1.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 769.00K | 1.21M | 1.55M | 60.00K | 13.00K |
| Income Before Tax | -11.28M | -12.34M | -4.04M | -2.83M | -1.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.14M | -1.55M | 1.00K | 5.00K |
| Net Income | -10.11M | -11.20M | -2.50M | -2.83M | -1.23M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| EPS Diluted | -0.83 | -0.97 | -1.29 | -1.46 | -0.63 |
| Weighted Avg Shares Out | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
| Weighted Avg Shares Out (Dil) | 13.64M | 11.50M | 1.94M | 1.94M | 1.94M |
Why Is NeuroSense Therapeutics (NRSN) Stock Up 300% Today?
Hottest Penny Stocks To Watch as March Comes to an End
Why NeuroSense Shares Are Soaring Today
Top Penny Stocks to Buy in March 2022, 3 For Your List
NeuroSense Therapeutics to Present at BIO CEO & Investor Conference
NeuroSense: Advancing Generic Combos In Neurodegenerative Diseases
Source: https://incomestatements.info
Category: Stock Reports